Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. METHODS: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. RESULTS: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). CONCLUSIONS: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive glucose control (A1C levels <7% in T2D and <7.5% in T1D) in several clinical trials was found to reduce the risk of incident albuminuria (A2) and DKD onset.70,78,90,406–410”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“Finally, in the UKPDS, wherein intensive treatment led to a mean end point A1C of 7.0%, hypoglycemia occurred in 1.8% of insulin-treated persons per year in the intensive group vs 0.7% of conventionally treated persons per year.407”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Takayama F, 1998, Cell Mol Biol, 44, 1101
Cited by
Items 101–200 of 1,004
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30156-5 · Cited by 338
Grundy, S. M., Arai, H., Barter, P., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A., Davidson, M. H., Genest, J., Kesäniemi, Y. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 327
Zannad, F., Kessler, M., Lehert, P., Grünfeld, J. P., Thuilliez, C., Leizorovicz, A., Lechat, P., & for the Fosidial Investigators (2006) · Kidney International · doi:10.1038/sj.ki.5001657 · Cited by 332
Susan Hedayati, S., Yalamanchili, V., & Finkelstein, F. O. (2012) · Kidney International · doi:10.1038/ki.2011.358 · Cited by 319
Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?
Valdivielso, J. M., Rodríguez-Puyol, D., Pascual, J., Barrios, C., Bermúdez-López, M., Sánchez-Niño, M. D., Pérez-Fernández, M., & Ortiz, A. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312705 · Cited by 305
Ridker, P. M., MacFadyen, J. G., Glynn, R. J., Koenig, W., Libby, P., Everett, B. M., Lefkowitz, M., Thuren, T., & Cornel, J. H. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.490 · Cited by 297
Dixon, B. S. (2006) · Kidney International · doi:10.1038/sj.ki.5001747 · Cited by 327
Lentine, K. L., Costa, S. P., Weir, M. R., Robb, J. F., Fleisher, L. A., Kasiske, B. L., Carithers, R. L., Ragosta, M., Bolton, K., Auerbach, A. D., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823eb07a · Cited by 314
Ezetimibe therapy: mechanism of action and clinical update
Toth, P., Phan, & Dayspring, T. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 288
p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease
Meijers, B. K. I., Claes, K., Bammens, B., de Loor, H., Viaene, L., Verbeke, K., Kuypers, D., Vanrenterghem, Y., & Evenepoel, P. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07971109 · Cited by 316
SHARP Collaborative Group (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.08.012 · Cited by 319
Risk factor paradox in wasting diseases
Kalantar-Zadeh, K., Horwich, T. B., Oreopoulos, A., Kovesdy, C. P., Younessi, H., Anker, S. D., & Morley, J. E. (2007) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e3281a30594 · Cited by 309
The heart and vascular system in dialysis
Wanner, C., Amann, K., & Shoji, T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30508-6 · Cited by 303
Self-citationReith, C., Baigent, C., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Holland, L., Wilson, K., Armitage, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01545-8 · Cited by 264
Self-citationLucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
Qunibi, W., Moustafa, M., Muenz, L. R., He, D. Y., Kessler, P. D., Diaz-Buxo, J. A., & Budoff, M. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.02.298 · Cited by 311
Cardiovascular Complications of Diabetic Kidney Disease
Pálsson, R., & Patel, U. D. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.003 · Cited by 292
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.072 · Cited by 302
McKinney, J. S., & Kostis, W. J. (2012) · Stroke · doi:10.1161/strokeaha.112.655894 · Cited by 294
NON‐CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Sudden Cardiac Death and Dialysis Patients
Herzog, C. A., Mangrum, J. M., & Passman, R. (2008) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2008.00455.x · Cited by 290
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 285
2007 WRITING COMMITTEE MEMBERS, Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 272
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Chronic kidney disease and cardiovascular complications
Di Lullo, L., House, A., Gorini, A., Santoboni, A., Russo, D., & Ronco, C. (2015) · Heart Failure Reviews · doi:10.1007/s10741-014-9460-9 · Cited by 262
The analysis of survival data: the Kaplan–Meier method
Jager, K. J., van Dijk, P. C., Zoccali, C., & Dekker, F. W. (2008) · Kidney International · doi:10.1038/ki.2008.217 · Cited by 259
Cortisol on Circadian Rhythm and Its Effect on Cardiovascular System
Mohd Azmi, N. A. S., Juliana, N., Azmani, S., Mohd Effendy, N., Abu, I. F., Mohd Fahmi Teng, N. I., & Das, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18020676 · Cited by 232
Disorders of lipid metabolism. Clinical Guidelines 2023
Ezhov, M. V., Kukharchuk, V. V., Sergienko, I. V., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Aronov, D. M., Arutyunov, G. P., Akhmedzhanov, N. M., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 219
Charytan, D., & Kuntz, R. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001934 · Cited by 271
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
Molitch, M. E., Adler, A. I., Flyvbjerg, A., Nelson, R. G., So, W.-Y., Wanner, C., Kasiske, B. L., Wheeler, D. C., de Zeeuw, D., & Mogensen, C. E. (2015) · Kidney International · doi:10.1038/ki.2014.128 · Cited by 268
Self-citationStatin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Romagnani, P., Agarwal, R., Chan, J. C. N., Levin, A., Kalyesubula, R., Karam, S., Nangaku, M., Rodríguez-Iturbe, B., & Anders, H.-J. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00589-9 · Cited by 184
Drechsler, C., Pilz, S., Obermayer-Pietsch, B., Verduijn, M., Tomaschitz, A., Krane, V., Espe, K., Dekker, F., Brandenburg, V., Marz, W., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq246 · Cited by 258
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., & Fuller, J. H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.022 · Cited by 255
Cobo, G., Hecking, M., Port, F. K., Exner, I., Lindholm, B., Stenvinkel, P., & Carrero, J. J. (2016) · Clinical Science · doi:10.1042/cs20160047 · Cited by 238
A systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253
Longitudinal Associations Between Dietary Protein Intake and Survival in Hemodialysis Patients
Shinaberger, C. S., Kilpatrick, R. D., Regidor, D. L., McAllister, C. J., Greenland, S., Kopple, J. D., & Kalantar-Zadeh, K. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.03.049 · Cited by 249
2023 Chinese guideline for lipid management
Li, J.-J., Zhao, S.-P., Zhao, D., Lu, G.-P., Peng, D.-Q., Liu, J., Chen, Z.-Y., Guo, Y.-L., Wu, N.-Q., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 223
Serum Phosphate and Mortality in Patients with Chronic Kidney Disease
Eddington, H., Hoefield, R., Sinha, S., Chrysochou, C., Lane, B., Foley, R. N., Hegarty, J., New, J., O'Donoghue, D. J., Middleton, R. J., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00810110 · Cited by 244
Parikh, N. I., Hwang, S.-J., Larson, M. G., Meigs, J. B., Levy, D., & Fox, C. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1884 · Cited by 237
Association between Serum Lipids and Survival in Hemodialysis Patients and Impact of Race
Kilpatrick, R. D., McAllister, C. J., Kovesdy, C. P., Derose, S. F., Kopple, J. D., & Kalantar-Zadeh, K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070795 · Cited by 233
Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective
Zoccali, C. (2006) · Kidney International · doi:10.1038/sj.ki.5000417 · Cited by 236
Atherosclerosis in CKD: differences from the general population
Drüeke, T. B., & Massy, Z. A. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.143 · Cited by 227
Allopurinol Benefits Left Ventricular Mass and Endothelial Dysfunction in Chronic Kidney Disease
Kao, M. P., Ang, D. S., Gandy, S. J., Nadir, M. A., Houston, J. G., Lang, C. C., & Struthers, A. D. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111185 · Cited by 226
Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease
Hung, S., Kuo, K., Wu, C., & Tarng, D. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005022 · Cited by 214
How Evidence-Based Are the Recommendations in Evidence-Based Guidelines?
McAlister, F. A., van Diepen, S., Padwal, R. S., Johnson, J. A., & Majumdar, S. R. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040250 · Cited by 227
CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies
Reiss, A. B., Miyawaki, N., Moon, J., Kasselman, L. J., Voloshyna, I., D'Avino, R., & De Leon, J. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.046 · Cited by 219
Tonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2453 · Cited by 226
Self-citation2018 Guidelines for the management of dyslipidemia
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.188 · Cited by 213
Why Is Protein–Energy Wasting Associated With Mortality in Chronic Kidney Disease?
Kovesdy, C. P., & Kalantar-Zadeh, K. (2009) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2008.10.002 · Cited by 218
Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options
Kao, M. P. C., Ang, D. S. C., Pall, A., & Struthers, A. D. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2009.70 · Cited by 220
Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini, A. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac020 · Cited by 190
Ridker, P. M., MacFadyen, J., Cressman, M., & Glynn, R. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.020 · Cited by 220
Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease
Tonelli, M., Karumanchi, S. A., & Thadhani, R. (2016) · Circulation · doi:10.1161/circulationaha.115.018713 · Cited by 213
. Prediction, progression and outcomes of chronic kidney disease in older adults.
Anderson, S., Halter, J. B., Hazzard, W. R., Himmelfarb, J., Horne, F. M., Kaysen, G. A., Kusek, J. W., Nayfield, S. G., Schmader, K., Tian, Y., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008080860 · Cited by 218
Nakano, T., Katsuki, S., Chen, M., Decano, J. L., Halu, A., Lee, L. H., Pestana, D. V. S., Kum, A. S. T., Kuromoto, R. K., Golden, W. S., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.034588 · Cited by 215
Mechanisms of vascular calcification in CKD—evidence for premature ageing?
Shanahan, C. M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.176 · Cited by 205
Colombo, P. C., Ganda, A., Lin, J., Onat, D., Harxhi, A., Iyasere, J. E., Uriel, N., & Cotter, G. (2012) · Heart Failure Reviews · doi:10.1007/s10741-011-9261-3 · Cited by 210
Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial
Charytan, D. M., Sabatine, M. S., Pedersen, T. R., Im, K., Park, J.-G., Pineda, A. L., Wasserman, S. M., Deedwania, P., Olsson, A. G., Sever, P. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.513 · Cited by 210
Son, B.-K., Kozaki, K., Iijima, K., Eto, M., Kojima, T., Ota, H., Senda, Y., Maemura, K., Nakano, T., Akishita, M., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000218859.90970.8d · Cited by 206
Hajhosseiny, R., Khavandi, K., & Goldsmith, D. J. (2013) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02954.x · Cited by 206
Cleland, J. G. F., McMurray, J. J. V., Kjekshus, J., Cornel, J. H., Dunselman, P., Fonseca, C., Hjalmarson, Å., Korewicki, J., Lindberg, M., Ranjith, N., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.041 · Cited by 203
Carbamylation of Serum Albumin as a Risk Factor for Mortality in Patients with Kidney Failure
Berg, A. H., Drechsler, C., Wenger, J., Buccafusca, R., Hod, T., Kalim, S., Ramma, W., Parikh, S. M., Steen, H., Friedman, D. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005218 · Cited by 200
Self-citationManaging Dyslipidemia in Chronic Kidney Disease
Harper, C. R., & Jacobson, T. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.025 · Cited by 204
Seiler, S., Reichart, B., Roth, D., Seibert, E., Fliser, D., & Heine, G. H. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq309 · Cited by 198
Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment
Berl, T., & Henrich, W. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00730805 · Cited by 201
Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
Yamamoto, S., Yancey, P. G., Ikizler, T. A., Jerome, W. G., Kaseda, R., Cox, B., Bian, A., Shintani, A., Fogo, A. B., Linton, M. F., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.013 · Cited by 199
Dyslipidemia in patients with chronic kidney disease
Hager, M. R., Narla, A. D., & Tannock, L. R. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9402-z · Cited by 186
Hou, W., Lv, J., Perkovic, V., Yang, L., Zhao, N., Jardine, M. J., Cass, A., Zhang, H., & Wang, H. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht065 · Cited by 192
2018 Guidelines for the Management of Dyslipidemia in Korea
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.78 · Cited by 192
Diets and enteral supplements for improving outcomes in chronic kidney disease
Kalantar-Zadeh, K., Cano, N. J., Budde, K., Chazot, C., Kovesdy, C. P., Mak, R. H., Mehrotra, R., Raj, D. S., Sehgal, A. R., Stenvinkel, P., et al. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.60 · Cited by 192
Hemodialysis‐induced cardiovascular disease
Ahmadmehrabi, S., & Tang, W. H. W. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12694 · Cited by 175
Vascular Incompetence in Dialysis Patients—Protein‐Bound Uremic Toxins and Endothelial Dysfunction
Jourde‐Chiche, N., Dou, L., Cerini, C., Dignat‐George, F., & Brunet, P. (2011) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2011.00925.x · Cited by 187
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Impaired β-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD
Afshinnia, F., Rajendiran, T. M., Soni, T., Byun, J., Wernisch, S., Sas, K. M., Hawkins, J., Bellovich, K., Gipson, D., Michailidis, G., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017030350 · Cited by 183
Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-Analysis
Hackam, D. G., Woodward, M., Newby, L. K., Bhatt, D. L., Shao, M., Smith, E. E., Donner, A., Mamdani, M., Douketis, J. D., Arima, H., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.055269 · Cited by 187
Mancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., & Pope, J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.05.007 · Cited by 188
Homoarginine, Cardiovascular Risk, and Mortality
März, W., Meinitzer, A., Drechsler, C., Pilz, S., Krane, V., Kleber, M. E., Fischer, J., Winkelmann, B. R., Böhm, B. O., Ritz, E., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.908988 · Cited by 185
Self-citationAcute Myocardial Infarction and Kidney Transplantation
Kasiske, B. L., Maclean, J. R., & Snyder, J. J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005090984 · Cited by 187
Hepatitis C Virus and Death Risk in Hemodialysis Patients
Kalantar-Zadeh, K., Kilpatrick, R. D., McAllister, C. J., Miller, L. G., Daar, E. S., Gjertson, D. W., Kopple, J. D., & Greenland, S. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070736 · Cited by 181
Dyslipidemia Associated with Chronic Kidney Disease
Tsimihodimos, V., Mitrogianni, Z., & Elisaf, M. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010041 · Cited by 174
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Sozio, S. M., Armstrong, P. A., Coresh, J., Jaar, B. G., Fink, N. E., Plantinga, L. C., Powe, N. R., & Parekh, R. S. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.01.261 · Cited by 179
Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients
O’Regan, C., Wu, P., Arora, P., Perri, D., & Mills, E. J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.06.033 · Cited by 182
Williams, M. E., Lacson, E., Teng, M., Ofsthun, N., & Lazarus, J. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001789 · Cited by 181
Cheng, X. S., VanWagner, L. B., Costa, S. P., Axelrod, D. A., Bangalore, S., Norman, S. P., Herzog, C. A., Lentine, K. L., & on behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Cardiovascular Radiology and Intervention (2022) · Circulation · doi:10.1161/cir.0000000000001104 · Cited by 161
The association of sudden cardiac death with inflammation and other traditional risk factors
Parekh, R. S., Plantinga, L. C., Kao, W. H. L., Meoni, L. A., Jaar, B. G., Fink, N. E., Powe, N. R., Coresh, J., & Klag, M. J. (2008) · Kidney International · doi:10.1038/ki.2008.449 · Cited by 181
Warfarin Dosing in Patients With Impaired Kidney Function
Limdi, N. A., Limdi, M. A., Cavallari, L., Anderson, A. M., Crowley, M. R., Baird, M. F., Allon, M., & Beasley, T. M. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.05.023 · Cited by 177
Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease
Badve, S. V., Roberts, M. A., Hawley, C. M., Cass, A., Garg, A. X., Krum, H., Tonkin, A., & Perkovic, V. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.04.041 · Cited by 175
C-Reactive Protein and Prediction of 1-Year Mortality in Prevalent Hemodialysis Patients
Bazeley, J., Bieber, B., Li, Y., Morgenstern, H., de Sequera, P., Combe, C., Yamamoto, H., Gallagher, M., Port, F. K., & Robinson, B. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00710111 · Cited by 175
Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era
Lazar, L. D., Pletcher, M. J., Coxson, P. G., Bibbins-Domingo, K., & Goldman, L. (2011) · Circulation · doi:10.1161/circulationaha.110.986349 · Cited by 174
Bonovas, S., Filioussi, K., Tsavaris, N., & Sitaras, N. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3560 · Cited by 172
Kalantar‐Zadeh, K. (2005) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2005.00074.x · Cited by 172
Stage IV Chronic Kidney Disease
Abboud, H., & Henrich, W. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0906797 · Cited by 163
Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Luvai, A., Mbagaya, W., Hall, A. S., & Barth, J. H. (2012) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s4324 · Cited by 189
Monocyte subpopulations and cardiovascular risk in chronic kidney disease
on behalf of the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association—European Dialysis and Transplant Association (ERA–EDTA), Heine, G. H., Ortiz, A., Massy, Z. A., Lindholm, B., Wiecek, A., Martínez-Castelao, A., Covic, A., Goldsmith, D., Süleymanlar, G., et al. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.41 · Cited by 165
Delahoy, P. J., Magliano, D. J., Webb, K., Grobler, M., & Liew, D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.017 · Cited by 168
Keating, G. M., & Croom, K. F. (2007) · Drugs · doi:10.2165/00003495-200767010-00013 · Cited by 169
Cardiovascular disease in chronic kidney disease
Marx-Schütt, K., Cherney, D. Z. I., Jankowski, J., Matsushita, K., Nardone, M., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf167 · Cited by 185
Metadata
- Authors
- Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E.
- Affiliations
- University of Würzburg (DE)
- Medical University of Graz (AT)
- University Medical Center Freiburg (DE)
- München Klinik Schwabing (DE)
- Pfizer (Germany) (DE)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-21
- Volume
- 353
- Issue
- 3
- Pages
- 238-248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110601215
- Cited by
- 2,614
- References
- 30
- Citations by year
- 2026: 74 · 2025: 51 · 2024: 66 · 2023: 76 · 2022: 90 · 2021: 92 · 2020: 97 · 2019: 110 · 2018: 96 · 2017: 104 · 2016: 110 · 2015: 132 · 2014: 153 · 2013: 162 · 2012: 185
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- atorvastatin, type 2 diabetes, hemodialysis, statins, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, LDL cholesterol, end-stage renal disease
- MeSH terms
- Atorvastatin, Aged, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Diseases, Renal Dialysis, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Pyrroles, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.